- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2013 (2013), Article ID 514914, 4 pages
No Association between FCγR3B Copy Number Variation and Susceptibility to Biopsy-Proven Giant Cell Arteritis
1Rheumatology Department, The Queen Elizabeth Hospital, Woodville South, SA 5011, Australia
2The Health Observatory, Discipline of Medicine, The University of Adelaide, Adelaide, SA 5005, Australia
3Discipline of Medicine, The University of Adelaide, Adelaide, SA 5005, Australia
4Centre for Eye Research, Royal Victorian Eye and Ear Hospital, University of Melbourne, East Melbourne, VIC 3002, Australia
5Lions Institute, University of Western Australia, Nedlands, WA 6009, Australia
Received 26 June 2013; Accepted 21 July 2013
Academic Editor: Bruce M. Rothschild
Copyright © 2013 Emma Dunstan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- A. T. Borchers and M. E. Gershwin, “Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment,” Autoimmunity Reviews, vol. 11, no. 6-7, pp. A544–A554, 2012.
- P. Ghosh, F. A. Borg, and B. Dasgupta, “Current understanding and management of giant cell arteritis and polymyalgia rheumatica,” Expert Review of Clinical Immunology, vol. 6, no. 6, pp. 913–928, 2010.
- E. Liozon, B. Ouattara, K. Rhaiem et al., “Familial aggregation in giant cell arteritis and polymyalgia rheumatica: a comprehensive literature review including 4 new families,” Clinical and Experimental Rheumatology, vol. 27, no. 1, pp. S89–S94, 2009.
- C. M. Weyand and J. J. Goronzy, “Functional domains on HLA-DR molecules: implications for the linkage of HLA-DR genes to different autoimmune diseases,” Clinical Immunology and Immunopathology, vol. 70, no. 2, pp. 91–98, 1994.
- C. M. Weyand, K. C. Hicok, G. G. Hunder, and J. J. Goronzy, “The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule,” Journal of Clinical Investigation, vol. 90, no. 6, pp. 2355–2361, 1992.
- P. Stankiewicz and J. R. Lupski, “Structural variation in the human genome and its role in disease,” Annual Review of Medicine, vol. 61, pp. 437–455, 2010.
- F. Nimmerjahn and J. V. Ravetch, “Fcγ receptors as regulators of immune responses,” Nature Reviews Immunology, vol. 8, no. 1, pp. 34–47, 2008.
- L. C. Willcocks, P. A. Lyons, M. R. Clatworthy et al., “Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake,” Journal of Experimental Medicine, vol. 205, no. 7, pp. 1573–1582, 2008.
- M. Fanciulli, P. J. Norsworthy, E. Petretto et al., “FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity,” Nature Genetics, vol. 39, no. 6, pp. 721–723, 2007.
- M. Mamtani, J.-M. Anaya, W. He, and S. K. Ahuja, “Association of copy number variation in the FCGR3B gene with risk of autoimmune diseases,” Genes and Immunity, vol. 11, no. 2, pp. 155–160, 2010.
- J. C. Nossent, M. Rischmueller, and S. Lester, “Low copy number of the Fc-γ receptor 3B gene FCGR3B is a risk factor for primary Sjogren's syndrome,” The Journal of Rheumatology, vol. 39, no. 11, pp. 2142–2147, 2012.
- S. W. Graf, S. Lester, J. C. Nossent et al., “Low copy number of the FCGR3B gene and rheumatoid arthritis: a case-control study and meta-analysis,” Arthritis Research and Therapy, vol. 14, no. 1, article R28, 2012.
- C. McKinney, M. Fanciulli, M. E. Merriman et al., “Association of variation in Fcγ receptor 3B gene copy number with rheumatoid arthritis in Caucasian samples,” Annals of the Rheumatic Diseases, vol. 69, no. 9, pp. 1711–1716, 2010.
- C. McKinney, J. C. A. Broen, M. C. Vonk et al., “Evidence that deletion at FCGR3B is a risk factor for systemic sclerosis,” Genes and Immunity, vol. 13, pp. 458–460, 2012.
- M. Phillipson and P. Kubes, “The neutrophil in vascular inflammation,” Nature Medicine, vol. 17, no. 11, pp. 1381–1390, 2011.
- C. McKinney and T. R. Merriman, “Meta-analysis confirms a role for deletion in FCGR3B in autoimmune phenotypes,” Human Molecular Genetics, vol. 21, no. 10, Article ID dds039, pp. 2370–2376, 2012.
- R. Black, S. Lester, E. Dunstan et al., “Fc-gamma receptor 3B copy number variation is not a risk factor for Behcet's disease,” International Journal of Rheumatology, vol. 2012, Article ID 167096, 4 pages, 2012.
- H. A. Niederer, L. C. Willcocks, T. F. Rayner et al., “Copy number, linkage disequilibrium and disease association in the FCGR locus,” Human Molecular Genetics, vol. 19, no. 16, pp. 3282–3294, 2010.
- W. B. Breunis, E. Van Mirre, J. Geissler et al., “Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B,” Human Mutation, vol. 30, no. 5, pp. E640–E650, 2009.
- X.-J. Zhou, J.-C. Lv, D.-F. Bu et al., “Copy number variation of FCGR3A rather than FCGR3B and FCGR2B is associated with susceptibility to anti-GBM disease,” International Immunology, vol. 22, no. 1, Article ID dxp113, pp. 45–51, 2009.
- H. A. Niederer, M. R. Clatworthy, L. C. Willcocks, and K. G. Smith, “FcgammaRIIB, FcgammaRIIIB, and systemic lupus erythematosus,” Annals of the New York Academy of Sciences, vol. 1183, pp. 69–88, 2010.
- C. C. Khor, S. Davila, W. B. Breunis et al., “Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease,” Nature Genetics, vol. 43, no. 12, pp. 1241–1246, 2011.
- A. W. Morgan, J. I. Robinson, J. H. Barrett et al., “Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis,” Arthritis Research and Therapy, vol. 8, no. 4, article R109, 2006.